{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:41:19Z","timestamp":1790476879260,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T00:00:00Z","timestamp":1562112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008966","name":"Soci\u00e9t\u00e9 Francophone du Diab\u00e8te","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008966","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.celrep.2019.07.009","type":"journal-article","created":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T13:46:19Z","timestamp":1565099179000},"page":"1447-1454.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["The GLP1R Agonist Liraglutide Reduces Hyperglucagonemia Induced by the SGLT2 Inhibitor Dapagliflozin via Somatostatin Release"],"prefix":"10.1016","volume":"28","author":[{"given":"Chiara","family":"Saponaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9ry","family":"Gmyr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Th\u00e9venet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ericka","family":"Moerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Delalleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Pasquetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anais","family":"Coddeville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Quenon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Daoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Vantyghem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Bousquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvan","family":"Martineau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Kerr-Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Staels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Pattou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bonner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.celrep.2019.07.009_bib1","doi-asserted-by":"crossref","first-page":"F889","DOI":"10.1152\/ajprenal.00267.2015","article-title":"Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus","volume":"309","author":"Abdul-Ghani","year":"2015","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.celrep.2019.07.009_bib2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13098-019-0438-6","article-title":"Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease","volume":"11","author":"Anholm","year":"2019","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.celrep.2019.07.009_bib3","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.celrep.2019.07.009_bib4","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2337\/dc16-1582","article-title":"Lowest Glucose Variability and Hypoglycemia Are Observed With the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION Study)","volume":"40","author":"Bajaj","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.celrep.2019.07.009_bib5","first-page":"543","article-title":"Development of the insulin secretory defect in genetically diabetic (db\/db) mouse","volume":"87","author":"Berglund","year":"1978","journal-title":"Acta Endocrinol. (Copenh.)"},{"key":"10.1016\/j.celrep.2019.07.009_bib6","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.celrep.2019.07.009_bib7","doi-asserted-by":"crossref","first-page":"44128","DOI":"10.1038\/srep44128","article-title":"The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis","volume":"7","author":"Chen","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.celrep.2019.07.009_bib8","doi-asserted-by":"crossref","first-page":"e898","DOI":"10.1371\/journal.pone.0000898","article-title":"Evidence based selection of housekeeping genes","volume":"2","author":"de Jonge","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1016\/j.celrep.2019.07.009_bib9","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.cmet.2010.04.007","article-title":"GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis","volume":"11","author":"De Marinis","year":"2010","journal-title":"Cell Metab."},{"key":"10.1016\/j.celrep.2019.07.009_bib10","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/dom.12982","article-title":"Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor","volume":"19","author":"DeFronzo","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.celrep.2019.07.009_bib11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0026-0495(89)90129-7","article-title":"Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake","volume":"38","author":"DeFronzo","year":"1989","journal-title":"Metabolism"},{"key":"10.1016\/j.celrep.2019.07.009_bib12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1210\/er.2006-0026","article-title":"The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications","volume":"28","author":"Dunning","year":"2007","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.celrep.2019.07.009_bib13","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1007\/s00125-005-1878-0","article-title":"Alpha cell function in health and disease: influence of glucagon-like peptide-1","volume":"48","author":"Dunning","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.celrep.2019.07.009_bib14","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.celrep.2019.07.009_bib15","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2337\/dc15-0355","article-title":"Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition","volume":"38","author":"Ferrannini","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.celrep.2019.07.009_bib16","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"Fr\u00edas","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.celrep.2019.07.009_bib17","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1111\/dom.13296","article-title":"Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial","volume":"20","author":"Fr\u00edas","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.celrep.2019.07.009_bib18","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/dom.12897","article-title":"Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: Sequential or simultaneous start?","volume":"19","author":"Goncalves","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.celrep.2019.07.009_bib19","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s00125-018-4772-2","article-title":"Use of human islets to understand islet biology and diabetes: progress, challenges and suggestions","volume":"62","author":"Hart","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.celrep.2019.07.009_bib20","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1126\/science.153.3740.1127","article-title":"Diabetes, a new mutation in the mouse","volume":"153","author":"Hummel","year":"1966","journal-title":"Science"},{"key":"10.1016\/j.celrep.2019.07.009_bib21","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/dom.13206","article-title":"Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study","volume":"20","author":"Jabbour","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.celrep.2019.07.009_bib22","doi-asserted-by":"crossref","first-page":"E1107","DOI":"10.1152\/ajpendo.00207.2012","article-title":"SSTR2 is the functionally dominant somatostatin receptor in human pancreatic \u03b2- and \u03b1-cells","volume":"303","author":"Kailey","year":"2012","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.celrep.2019.07.009_bib23","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/dmr.5610050306","article-title":"Human ketone body production and utilization studied using tracer techniques: regulation by free fatty acids, insulin, catecholamines, and thyroid hormones","volume":"5","author":"Keller","year":"1989","journal-title":"Diabetes Metab. Rev."},{"key":"10.1016\/j.celrep.2019.07.009_bib24","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1097\/TP.0b013e3181d154ac","article-title":"Upgrading pretransplant human islet culture technology requires human serum combined with media renewal","volume":"89","author":"Kerr-Conte","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.celrep.2019.07.009_bib25","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S2213-8587(18)30023-8","article-title":"Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial","volume":"6","author":"Ludvik","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.celrep.2019.07.009_bib26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/dom.12779","article-title":"Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes","volume":"19","author":"Lundkvist","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.celrep.2019.07.009_bib27","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.celrep.2019.07.009_bib28","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.2337\/db17-1278","article-title":"Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy","volume":"67","author":"Martinez","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.celrep.2019.07.009_bib29","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3164\/jcbn.13-14","article-title":"Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes","volume":"53","author":"Matsumoto","year":"2013","journal-title":"J.\u00a0Clin. Biochem. Nutr."},{"key":"10.1016\/j.celrep.2019.07.009_bib30","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2337\/diabetes.55.04.06.db05-1449","article-title":"Postprandial suppression of glucagon secretion depends on intact pulsatile insulin secretion: further evidence for the intraislet insulin hypothesis","volume":"55","author":"Meier","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.celrep.2019.07.009_bib31","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.celrep.2019.07.009_bib32","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1210\/jc.2014-3472","article-title":"Dapagliflozin lowers plasma glucose concentration and improves \u03b2-cell function","volume":"100","author":"Merovci","year":"2015","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.celrep.2019.07.009_bib33","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1530\/JOE-17-0263","article-title":"Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice","volume":"234","author":"Millar","year":"2017","journal-title":"J.\u00a0Endocrinol."},{"key":"10.1016\/j.celrep.2019.07.009_bib34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJM197007162830301","article-title":"Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion","volume":"283","author":"M\u00fcller","year":"1970","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.celrep.2019.07.009_bib35","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s00125-017-4315-2","article-title":"The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice","volume":"60","author":"\u00d8rgaard","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.celrep.2019.07.009_bib36","doi-asserted-by":"crossref","first-page":"31214","DOI":"10.1038\/srep31214","article-title":"Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells","volume":"6","author":"Pedersen","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.celrep.2019.07.009_bib37","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1172\/JCI29103","article-title":"Islet beta cell failure in type 2 diabetes","volume":"116","author":"Prentki","year":"2006","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.celrep.2019.07.009_bib38","doi-asserted-by":"crossref","first-page":"e13852","DOI":"10.14814\/phy2.13852","article-title":"GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P\/Q-type Ca2+ channels","volume":"6","author":"Ramracheya","year":"2018","journal-title":"Physiol. Rep."},{"key":"10.1016\/j.celrep.2019.07.009_bib39","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2337\/db10-1032","article-title":"Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy","volume":"59","author":"Rizza","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.celrep.2019.07.009_bib40","doi-asserted-by":"crossref","first-page":"610","DOI":"10.2337\/diacare.13.6.610","article-title":"Glucose toxicity","volume":"13","author":"Rossetti","year":"1990","journal-title":"Diabetes Care"},{"key":"10.1016\/j.celrep.2019.07.009_bib41","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0300-595X(86)80041-X","article-title":"Intra-islet insulin-glucagon-somatostatin relationships","volume":"15","author":"Samols","year":"1986","journal-title":"Clin. Endocrinol. Metab."},{"key":"10.1016\/j.celrep.2019.07.009_bib42","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2337\/db17-1331","article-title":"Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes","volume":"67","author":"Shankar","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.celrep.2019.07.009_bib43","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1172\/JCI81975","article-title":"GLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation","volume":"125","author":"Shigeto","year":"2015","journal-title":"J.\u00a0Clin. Invest."},{"issue":"1S","key":"10.1016\/j.celrep.2019.07.009_bib44","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.amjcard.2017.05.013","article-title":"Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms","volume":"120","author":"Staels","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.celrep.2019.07.009_bib45","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/j.gastro.2016.03.003","article-title":"Glucose-Dependent Insulinotropic Peptide Stimulates Glucagon-Like Peptide 1 Production by Pancreatic Islets via Interleukin 6, Produced by \u03b1 Cells","volume":"151","author":"Timper","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.celrep.2019.07.009_bib46","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/2042018814559725","article-title":"GLP-1 receptor agonists: a review of head-to-head clinical studies","volume":"6","author":"Trujillo","year":"2015","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"10.1016\/j.celrep.2019.07.009_bib47","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJM197108192850806","article-title":"Glucagon physiology and pathophysiology","volume":"285","author":"Unger","year":"1971","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.celrep.2019.07.009_bib48","first-page":"E1015","article-title":"Effects of glucagon-like peptide-I on glucose turnover in rats","volume":"270","author":"Van Dijk","year":"1996","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.celrep.2019.07.009_bib49","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1210\/jc.2015-3906","article-title":"Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin","volume":"101","author":"Vanderheiden","year":"2016","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.celrep.2019.07.009_bib50","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1464-5491.2007.02333.x","article-title":"Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus","volume":"25","author":"Vilsb\u00f8ll","year":"2008","journal-title":"Diabet. Med."},{"issue":"Suppl 1","key":"10.1016\/j.celrep.2019.07.009_bib51","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1463-1326.2011.01450.x","article-title":"Regulation of glucagon secretion by glucose: paracrine, intrinsic or both?","volume":"13","author":"Walker","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.celrep.2019.07.009_bib52","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/modpathol.2014.113","article-title":"Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas","volume":"28","author":"Waser","year":"2015","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.celrep.2019.07.009_bib53","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1210\/mend.11.11.0016","article-title":"Somatostatin receptor subtype 2 knockout mice are refractory to growth hormone-negative feedback on arcuate neurons","volume":"11","author":"Zheng","year":"1997","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.celrep.2019.07.009_bib54","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N.\u00a0Engl. J. Med."}],"container-title":["Cell Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221112471930899X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221112471930899X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T10:43:17Z","timestamp":1761907397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221112471930899X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S221112471930899X"],"URL":"https:\/\/doi.org\/10.1016\/j.celrep.2019.07.009","relation":{},"ISSN":["2211-1247"],"issn-type":[{"value":"2211-1247","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The GLP1R Agonist Liraglutide Reduces Hyperglucagonemia Induced by the SGLT2 Inhibitor Dapagliflozin via Somatostatin Release","name":"articletitle","label":"Article Title"},{"value":"Cell Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.celrep.2019.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s).","name":"copyright","label":"Copyright"}]}}